블로그
- Dual targeting CDK4/6 and CDK7 augments tumor response and anti-tumor immunity in breast cancer... kinase 4/6 inhibitors (CDK4/6i) have transformed the treatment landscape for hormone receptor-positive (HR resistance in both HR+ and TNBC models.
- [얼바인 스토리] 2025 Beast of the East [얼바인 스토리] 2025 Beast of the East 2025 Beast of the East in the book As of May 20 2025 HR - CA (1st) US Tons of amazing talent out here and our team fought hard till the end.
- [꿈을 잇다-글로벌 한상드림] 어학일지 DAY 18 I shot an email to HR to take a look at your files. As you know, everything here, including performance, is metrics based.